Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–2 of 2 stories
The discussion highlights the transformative impact of CAR T therapy, specifically obe-cel, on the treatment of acute lymphoblastic leukemia (ALL). Clinical trial data suggests improved efficacy and safety outcomes, emphasizing the need for oncology pharmacists to manage toxicity and coordinate care effectively.
Read full storyReal-world data confirms that inotuzumab ozogamicin significantly improves remission rates in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), with a 51.7% overall survival rate. The study highlights a 71.4% MRD-negative status in patients, facilitating further treatment options like ASCT or CAR T.
Get the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.